VIGONVITA-B, the stock of Vigonvita Life Sciences Co Ltd, skyrocketed by 175.85% during its debut on the Hong Kong Stock Exchange. The biopharmaceutical company's shares opened with a bang in the morning session, showcasing strong investor enthusiasm for the newly listed entity.

The company's initial public offering (IPO) garnered significant attention from both retail and institutional investors. The Hong Kong public offer portion was massively oversubscribed by 6,238.42 times, leading to a final allocation of 1.76 million shares, representing 10% of the total offering. The international offering also saw robust demand, being 16.87 times oversubscribed, with a final allocation of 15.8 million shares, accounting for 90% of the total shares offered.

Vigonvita Life Sciences had set its final offer price at HK$33.37 per H share for the global offering. The strong debut performance, significantly surpassing the offer price, reflects high market confidence in the company's prospects and the current appetite for biopharmaceutical stocks in the Hong Kong market. This impressive listing adds Vigonvita to the growing list of successful biotech IPOs in the region, highlighting the sector's attractiveness to investors.